Dynamic Advisor Solutions LLC Sells 65,438 Shares of Pfizer Inc. (NYSE:PFE)

Dynamic Advisor Solutions LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 35.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 118,651 shares of the biopharmaceutical company’s stock after selling 65,438 shares during the quarter. Dynamic Advisor Solutions LLC’s holdings in Pfizer were worth $3,293,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of PFE. GoalVest Advisory LLC increased its holdings in shares of Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares during the period. Creekmur Asset Management LLC bought a new position in shares of Pfizer in the fourth quarter worth $32,000. VisionPoint Advisory Group LLC increased its holdings in shares of Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the period. Tennessee Valley Asset Management Partners bought a new position in shares of Pfizer in the fourth quarter worth $36,000. Finally, DiNuzzo Private Wealth Inc. bought a new position in shares of Pfizer in the fourth quarter worth $37,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 1.3 %

NYSE PFE traded down $0.36 during trading on Tuesday, hitting $28.00. 14,917,681 shares of the company’s stock traded hands, compared to its average volume of 41,066,023. The stock has a fifty day moving average of $27.72 and a two-hundred day moving average of $27.70. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $37.80. The firm has a market cap of $158.66 billion, a P/E ratio of -470.09, a PEG ratio of 1.09 and a beta of 0.70.

Pfizer (NYSE:PFE) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The company had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. Pfizer’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.23 earnings per share. As a group, sell-side analysts expect that Pfizer Inc. will post 2.37 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 14th. Stockholders of record on Friday, May 10th were issued a dividend of $0.42 per share. The ex-dividend date was Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.00%. Pfizer’s dividend payout ratio is currently -2,799.53%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on PFE. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Morgan Stanley upped their target price on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 target price (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Monday, June 17th. Ten research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $35.86.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.